AG真人官方

Amendment No. 4 to Schedule 13D discloses that Kenneth D. Tuchman and related entities collectively own 27,853,207 TTEC common shares, or 58.2 % of the outstanding 47.8 million shares. The ownership is split among KDT Family, LLLP (14.8 M, 30.9 %), KDT Stock Revocable Trust (6.55 M, 13.7 %), Mantucket Capital Management Corp. (14.8 M, 30.9 %) and Mr. Tuchman personally (6.53 M, 13.6 %).

The amendment鈥檚 key development is that on 31 Jul 2025 Mr. Tuchman withdrew his previously announced non-binding proposal to acquire the remaining TTEC shares he does not already own for $6.85 per share in cash. A copy of the withdrawal letter is attached as Exhibit 99.1. No other transactions occurred in the past 60 days and no new contractual arrangements were disclosed beyond the withdrawal.

While the reporting persons state they will continue to monitor their investment and may pursue future actions, the immediate effect is the removal of a potential take-private premium, leaving public shareholders dependent on fundamental performance rather than a buy-out catalyst.

Item 5.02 8-K: On 18 Jul 2025 Lixte Biotechnology appointed Jason Sawyer and Dr. Michael Holloway as independent directors under designation rights granted to investors that bought 3,573,190 Series B Preferred Shares on 3 Jul 2025. Sawyer also becomes Chair of the Compensation Committee and joins the Audit Committee.

To accommodate the appointments, Dr. Stephen Forman and Dr. Yun Yen resigned from the Board and moved to the company鈥檚 Scientific Advisory Committee. The company states these departures were not due to disagreements.

Separately, Chief Medical Officer Dr. Jan Schellens tendered his resignation and his consulting agreement will end 31 Jul 2025 so he can pursue other opportunities; no disputes were cited.

No financial results, guidance, or operational metrics were provided鈥攖his filing is strictly a corporate-governance update linked to the recent preferred-equity financing.

Novanta Inc. (NASDAQ: NOVT) entered into a Fourth Amended & Restated Credit Agreement on 27 June 2025 that replaces its 2019 facility scheduled to mature in March 2027. The new agreement provides an aggregate senior secured credit capacity of approximately US$1.0 billion, broken down into:

• 鈧�65.31 million 5-year Euro-denominated term loan
• $75 million 5-year US-dollar term loan
• $850 million 5-year revolving credit facility

The maturity is extended to June 2030, and an uncommitted accordion feature can raise total commitments by an additional $350 million, subject to customary conditions. Interest is set at (i) Base Rate + 0鈥�0.75 ppt or (ii) SOFR/SONIA/EURIBOR + 1.00鈥�1.75 ppt, with pricing tied to the company鈥檚 consolidated leverage ratio. A commitment fee applies to unused revolver capacity.

Key financial covenants tested quarterly include: (1) maximum consolidated leverage ratio of 3.5脳 (step-up to 4.0脳 for four quarters following qualifying acquisitions >= $50 million) and (2) minimum fixed-charge coverage ratio of 1.25脳. The facilities are secured by senior liens on substantially all assets of Novanta and certain subsidiaries and contain customary negative covenants on mergers, asset sales, indebtedness, investments and liens.

Required quarterly principal amortization begins September 2025 for the Euro term loan and September 2026 for the US term loan, with final balloon payments due at maturity. Prepayments from asset sales, casualty events or incremental debt are mandatory, while voluntary prepayments and commitment reductions are permitted without premium.

Outstanding borrowings under the prior facility were $392.4 million as of 28 March 2025. The new structure enhances liquidity headroom, extends tenor, and provides interest-rate optionality, but also secures the debt and maintains leverage limits that investors should monitor.